JP2010522540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522540A5 JP2010522540A5 JP2009554098A JP2009554098A JP2010522540A5 JP 2010522540 A5 JP2010522540 A5 JP 2010522540A5 JP 2009554098 A JP2009554098 A JP 2009554098A JP 2009554098 A JP2009554098 A JP 2009554098A JP 2010522540 A5 JP2010522540 A5 JP 2010522540A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- rsv
- protein
- chimeric
- chimeric rsv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 23
- 241000725643 Respiratory syncytial virus Species 0.000 claims 15
- 108091006028 chimera Proteins 0.000 claims 13
- 108060003023 F Proteins 0.000 claims 7
- 108091006011 G proteins Proteins 0.000 claims 5
- 102000030007 GTP-Binding Proteins Human genes 0.000 claims 5
- 108091000058 GTP-Binding Proteins Proteins 0.000 claims 5
- 230000002163 immunogen Effects 0.000 claims 5
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 230000000240 adjuvant Effects 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000038129 antigens Human genes 0.000 claims 3
- 108091007172 antigens Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 229960001230 Asparagine Drugs 0.000 claims 1
- 108090001126 FURIN Proteins 0.000 claims 1
- 102000004961 Furin Human genes 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 229920000023 polynucleotide Polymers 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Claims (18)
- N末端からC末端の方向で、
(i)第1のFタンパク質ポリペプチドドメイン、
(ii)Gタンパク質ポリペプチドドメイン、および
(iii)第2のFタンパク質ポリペプチドドメイン
を含む、キメラ呼吸器合胞体ウイルス(RSV)ポリペプチド。 - 第1のFタンパク質ポリペプチドドメイン(i)がネイティブFタンパク質ポリペプチドの残基24〜残基107のアミノ酸配列を含む、請求項1に記載のキメラRSVポリペプチド。
- 第2のFタンパク質ポリペプチドドメイン(iii)がネイティブFタンパク質ポリペプチドの残基161〜残基524のアミノ酸配列を含む、請求項1から2のいずれかに記載のキメラRSVポリペプチド。
- シグナルペプチドをさらに含む、請求項1から3のいずれかに記載のキメラRSVポリペプチド。
- 天然に存在するRSV Fタンパク質中に存在するフューリン切断部位を排除する少なくとも1つのアミノ酸の欠失、付加または置換を含む、請求項1から4のいずれかに記載のキメラRSVポリペプチド。
- Gタンパク質ポリペプチドドメイン(ii)がネイティブGタンパク質ポリペプチドの少なくとも1つの免疫優勢のT細胞エピトープを含む、請求項1から5のいずれかに記載のキメラRSVポリペプチド。
- 免疫優勢のT細胞エピトープがネイティブGタンパク質ポリペプチドのアミノ酸残基183〜残基203を含む、請求項6に記載のキメラRSVポリペプチド。
- Gタンパク質の残基191でアスパラギンからアラニンへの置換(N191A)を含む、請求項6または7に記載のキメラRSVポリペプチド。
- 前記請求項のいずれかに記載のキメラRSVポリペプチドの多量体を含む組換えRSV抗原。
- 請求項1から9のいずれかに記載のキメラRSVポリペプチド、および担体または賦形剤を含む、免疫原性組成物。
- アジュバントをさらに含む、請求項10に記載の免疫原性組成物。
- アジュバントがTh1に偏らせるアジュバントである、請求項11に記載の免疫原性組成物。
- 医薬に使用するための、請求項10から12のいずれかに記載の免疫原性組成物。
- ヒト対象に投与した後にRSVの感染症の予防または減少に使用するための、請求項10から12のいずれかに記載の免疫原性組成物。
- 請求項1から8のいずれかに記載のキメラポリペプチドをコードしているポリヌクレオチド配列を含む組換え核酸。
- 請求項15に記載の核酸を含む、宿主細胞。
- RSV感染症を処置する医薬品の調製における、請求項1から8のいずれかに記載のキメラRSVポリペプチドまたは請求項9に記載の抗原の使用。
- 医薬品を、RSV感染症の予防的処置を目的として投与する、請求項17のキメラRSVポリペプチドまたは抗原の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89620107P | 2007-03-21 | 2007-03-21 | |
PCT/IB2008/001286 WO2008114149A2 (en) | 2007-03-21 | 2008-03-20 | Chimeric antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010522540A JP2010522540A (ja) | 2010-07-08 |
JP2010522540A5 true JP2010522540A5 (ja) | 2011-05-12 |
Family
ID=39766560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009554098A Pending JP2010522540A (ja) | 2007-03-21 | 2008-03-20 | キメラ抗原 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20100203071A1 (ja) |
EP (1) | EP2181121A4 (ja) |
JP (1) | JP2010522540A (ja) |
CA (1) | CA2684578A1 (ja) |
WO (1) | WO2008114149A2 (ja) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160000902A1 (en) * | 2003-07-11 | 2016-01-07 | Novavax, Inc. | Combination vaccine for respiratory syncytial virus and influenza |
PT2347775T (pt) | 2005-12-13 | 2020-07-14 | The President And Fellows Of Harvard College | Estruturas em andaime para transplante celular |
US9770535B2 (en) | 2007-06-21 | 2017-09-26 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
EP3508505A1 (en) | 2007-12-24 | 2019-07-10 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
JP5690143B2 (ja) | 2008-02-13 | 2015-03-25 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 持続的細胞プログラミング装置 |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
HUE051666T2 (hu) * | 2008-12-09 | 2021-03-29 | Novavax Inc | Módosított RSV F fehérjék és alkalmazásuk módszerei |
PL2445526T3 (pl) | 2009-06-24 | 2017-08-31 | Glaxosmithkline Biologicals S.A. | Rekombinowane antygeny rsv |
SG176807A1 (en) | 2009-06-24 | 2012-01-30 | Id Biomedical Corp Quebec | Vaccine |
WO2011008974A2 (en) | 2009-07-15 | 2011-01-20 | Novartis Ag | Rsv f protein compositions and methods for making same |
KR101425404B1 (ko) * | 2009-07-17 | 2014-08-01 | 한림대학교 산학협력단 | 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물 |
CA2768552A1 (en) * | 2009-07-31 | 2011-02-03 | President And Fellows Of Harvard College | Programming of cells for tolerogenic therapies |
AU2010279492B2 (en) * | 2009-08-04 | 2015-04-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of The Health And Human Services, Centers For Disease Control And Prevention | Anti-RSV immunogens and methods of immunization |
EP2590675B1 (en) | 2010-07-07 | 2018-08-29 | Artificial Cell Technologies, Inc. | Respiratory syncytial virus antigenic compositions and methods |
WO2012048165A2 (en) | 2010-10-06 | 2012-04-12 | President And Fellows Of Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
AU2012211126A1 (en) * | 2011-01-28 | 2013-07-18 | Medimmune, Llc | Expression of soluble viral fusion glycoproteins in mammalian cells |
US20140287022A1 (en) * | 2011-04-26 | 2014-09-25 | Molecular Express, Inc. | Liposomal formulations |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
EP2701745B1 (en) | 2011-04-28 | 2018-07-11 | President and Fellows of Harvard College | Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration |
EP2714073B1 (en) | 2011-06-03 | 2021-03-10 | President and Fellows of Harvard College | In situ antigen-generating cancer vaccine |
ES2395677B1 (es) * | 2011-07-29 | 2013-12-26 | Instituto De Salud Carlos Iii | Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma. |
WO2013031827A1 (ja) | 2011-08-29 | 2013-03-07 | 国立大学法人徳島大学 | Rsv粘膜ワクチン |
CN104080476A (zh) * | 2011-09-30 | 2014-10-01 | 诺瓦瓦克斯股份有限公司 | 用于呼吸道合胞病毒的重组纳米颗粒rsv f疫苗 |
EP3511337A1 (en) * | 2012-04-10 | 2019-07-17 | The Trustees of The University of Pennsylvania | Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same |
CA2870309C (en) | 2012-04-16 | 2024-02-20 | President And Fellows Of Harvard College | Mesoporous silica compositions for modulating immune responses |
EA201891945A3 (ru) * | 2012-08-01 | 2019-05-31 | Бавариан Нордик А/С | Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv) |
DK2879702T3 (da) * | 2012-08-01 | 2020-02-24 | Bavarian Nordic As | Rekombinant modificeret vacciniavirus ankara (mva)-vaccine mod respiratorisk syncytialvirus (rsv) |
US20140037680A1 (en) * | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
JP2015525794A (ja) * | 2012-08-06 | 2015-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法 |
US20140227309A1 (en) * | 2013-02-11 | 2014-08-14 | Novavax, Inc. | Combination vaccine for respiratory syncytial virus and influenza |
EP3492097A1 (en) | 2013-08-05 | 2019-06-05 | GlaxoSmithKline Biologicals S.A. | Combination immunogenic compositions |
US10682400B2 (en) | 2014-04-30 | 2020-06-16 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
EP3888676A1 (en) | 2014-06-13 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
US11150242B2 (en) | 2015-04-10 | 2021-10-19 | President And Fellows Of Harvard College | Immune cell trapping devices and methods for making and using the same |
CN114796474A (zh) | 2015-09-03 | 2022-07-29 | 诺瓦瓦克斯股份有限公司 | 具有改进的稳定性和免疫原性的疫苗组合物 |
AU2016379097C1 (en) | 2015-12-23 | 2021-04-08 | Pfizer Inc. | RSV F protein mutants |
CN115531609A (zh) | 2016-02-06 | 2022-12-30 | 哈佛学院校长同事会 | 重塑造血巢以重建免疫 |
CN115305229A (zh) | 2016-07-13 | 2022-11-08 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
SG11201900767VA (en) | 2016-08-03 | 2019-02-27 | Lonza Walkersville Inc | Method of detecting an endotoxin using limulus amebocyte lysate substantially free of coagulogen |
GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
US11352656B2 (en) * | 2017-01-11 | 2022-06-07 | Lonza Walkersville, Inc. | Coagulogen-free clarified limulus amebocyte lysate and chromogenic assay of endotoxin |
CN111328344A (zh) | 2017-10-16 | 2020-06-23 | 葛兰素史密丝克莱恩生物有限公司 | 增强的启动子 |
AR114989A1 (es) | 2017-10-16 | 2020-11-18 | Glaxosmithkline Biologicals Sa | Vectores adenovirales con dos casetes de expresión |
BR112020007008A2 (pt) | 2017-10-16 | 2020-11-17 | Glaxosmithkline Biologicals S.A. | vetores adenovirais com dois cassetes de expressão codificando proteínas antigênicas do rsv ou fragmentos das mesmas |
US11905313B2 (en) | 2017-11-28 | 2024-02-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services. | Recombinant RSV G proteins and their use |
AU2019238171A1 (en) | 2018-03-19 | 2020-09-24 | Novavax, Inc. | Multivalent influenza nanoparticle vaccines |
BR112020024285A2 (pt) | 2018-06-12 | 2021-03-02 | Glaxosmithkline Biologicals S.A. | polinucleotídeos e polipeptídeos de adenovírus |
KR20200050264A (ko) | 2018-11-01 | 2020-05-11 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
EP3932424A4 (en) | 2019-02-28 | 2022-10-12 | KM Biologics Co., Ltd. | F/G CHIMERIC VRS VACCINE |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU751022B2 (en) * | 1997-09-19 | 2002-08-08 | Wyeth Holdings Corporation | Peptides derived from the attachment (G) protein of respiratory syncytial virus |
-
2008
- 2008-03-20 EP EP08751012A patent/EP2181121A4/en not_active Withdrawn
- 2008-03-20 JP JP2009554098A patent/JP2010522540A/ja active Pending
- 2008-03-20 CA CA002684578A patent/CA2684578A1/en not_active Abandoned
- 2008-03-20 US US12/531,758 patent/US20100203071A1/en not_active Abandoned
- 2008-03-20 WO PCT/IB2008/001286 patent/WO2008114149A2/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010522540A5 (ja) | ||
HRP20161353T1 (hr) | Rekombinantni rsv antigeni | |
AU2016289492B2 (en) | Vaccine against RSV | |
JP2011528222A5 (ja) | ||
JP2018515088A5 (ja) | ||
JP2009520758A5 (ja) | ||
JP2008530245A5 (ja) | ||
JP2015512876A5 (ja) | ||
JP2012530504A5 (ja) | ||
AU2015255834B2 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
HRP20140109T1 (hr) | Novi imunoadjuvantni spojevi na bazi flagelina i njihova upotreba | |
JP2013517783A5 (ja) | ||
JP2010500399A5 (ja) | ||
JP2013515055A5 (ja) | ||
TWI455721B (zh) | 癌疫苗組合物 | |
JP2015504052A5 (ja) | ||
SI2797950T1 (en) | Fusion protein against cancer | |
KR102047072B1 (ko) | 메르스 코로나바이러스 핵단백질의 전장 단백질 유전자 및 이를 포함하는 메르스 코로나바이러스 감염 예방용 백신 조성물 | |
EP3972639A1 (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
JP2004538320A5 (ja) | ||
JP2008531463A5 (ja) | ||
CN102101889A (zh) | 一种非洲猪瘟病毒vp73基因的原核表达蛋白及其制备方法 | |
CN101336110B (zh) | 预防或治疗肝损伤的肽及其衍生物及其应用 | |
CA3193288A1 (en) | Immunogenic coronavirus fusion proteins and related methods | |
ES2551699T3 (es) | Composiciones, procedimientos y kits |